Semnur Pharmaceuticals, Inc. (SMNR): R&D Expense
$2.55M
Year ended 2025-12-31
$4.37M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.55M | +49.0% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $1.71M | n/a | 2026-02-27, From 2024-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Semnur Pharmaceuticals, Inc. (SMNR) | 2025-12-31 | $2.55M | +49.0% |
| Aspire Biopharma Holdings, Inc. (ASBP) | 2025-12-31 | $923.9K | +540.0% |
| Accustem Sciences Inc. (ACUT) | 2025-12-31 | $281.0K | +103.2% |
| NeuroSense Therapeutics Ltd. (NRSN) | 2025-12-31 | $6.23M | +9.3% |
| Ocean Biomedical, Inc. (OCEA) | 2024-12-31 | $26.0K | -96.3% |
| Alzamend Neuro, Inc. (ALZN) | 2026-04-30 | $3.63M | +156.5% |
| Inhibitor Therapeutics, Inc. (INTI) | 2025-12-31 | $1.70M | -3.5% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $12.54M | -24.3% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare SMNR, ASBP, ACUT, NRSN side by side · Screen every company in Pharmaceutical Preparations ↗